公开(公告)号：US20210386712A1

公开(公告)日：2021-12-16

申请号：US17458886

申请日：2021-08-27

Applicant: VICORE PHARMA AB

Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

IPC: A61K31/4178 ,  A61K38/21 ,  A61K31/513 ,  A61K31/706 ,  A61P31/14 ,  A61K31/573 ,  A61K31/16 ,  A61K45/06 ,  A61K31/7056

Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-thiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

公开(公告)号：US20230114153A1

公开(公告)日：2023-04-13

申请号：US17912645

申请日：2021-03-18

Applicant: Vicore Pharma AB

Inventor： Tomas Fex ,  Bengt Ohlsson ,  Johan Raud

IPC: A61K31/4178 ,  A61K31/192 ,  A61K31/138 ,  A61K31/428 ,  A61K31/635 ,  A61K31/675 ,  A61K31/405 ,  A61K38/13 ,  A61K31/167 ,  A61K31/58 ,  A61K31/4965 ,  A61K31/4418 ,  C07D409/10

Abstract: There is provided herein a compound of formula (I), wherein R1, R2, R3, R4, R5 and Z are as defined herein, for use in the treatment of a disease or condition in which activation of AT2 receptors is desired or required but in which inhibition of CYPs is not desired. Such compounds are particularly useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

公开(公告)号：US20210290596A1

公开(公告)日：2021-09-23

申请号：US17113416

申请日：2020-12-07

Applicant: Vicore Pharma AB

Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

IPC: A61K31/4178 ,  A61K45/06 ,  A61K31/573 ,  A61K38/21 ,  A61K31/706 ,  A61K31/16 ,  A61K31/7056 ,  A61K31/513 ,  A61P31/14

Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.

公开(公告)号：US11123329B1

公开(公告)日：2021-09-21

申请号：US17113416

申请日：2020-12-07

Applicant: Vicore Pharma AB

Inventor： Carl-Johan Dalsgaard ,  Johan Raud ,  Rohit Batta

IPC: A61K31/4178 ,  A61P31/14 ,  A61K31/16 ,  A61K31/573 ,  A61K38/21 ,  A61K45/06 ,  A61K31/513 ,  A61K31/7056 ,  A61K31/706

Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.